JPRN-UMIN000002893尚未招募未知
Inhalation of tobramycin for the patients with persistent respiratory infection by Psudomonas aeruginosa - Inhalation of tobramycin
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Cases with severe respiratory failure that require high density oxygen inhalation.
研究者
相似试验
已完成
3 期
ong-term inhaled nebulized tobramycin in patients with non-cystic fibrosis bronchiectasis. A randomized placebo controlled trial. The BATTLE study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy.bronchiectasis10006436NL-OMON47248Medisch Centrum Alkmaar58
招募中
3 期
Addition of Tobramycin inhalation antibiotic treatment to standard IV antibiotic treatment for ventilator-associated pneumoniaNL-OMON40796Erasmus MC, Universitair Medisch Centrum Rotterdam42
进行中（未招募）
不适用
asale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich.Nasal inhalation of tobramycin by the Pari Sinus nebulizer in patients with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways. - tobra nasal CF pilotsubjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airwaysEUCTR2008-000164-17-DEniversity of Jena14
进行中（未招募）
1 期
A study comparing Tobramycin Inhalation Powder (TIP) administered once daily continuously versus TIP administered BID in 28 day on / 28 day off cycles for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosisMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10021860Term: Infection Pseudomonas aeruginosaSystem Organ Class: 100000004862Cystic FibrosisEUCTR2016-004318-82-Outside-EU/EEAovartis Pharmaceuticals Corporation200
已完成
不适用
Tobramycin nebulisation with I-neb (TONI) study in children with cystic fibrosis: pharmacokinetics and safety'Cystic Fibrosis' en 'CF'100836241000401810024970NL-OMON39647Erasmus MC, Universitair Medisch Centrum Rotterdam24